Bayer Sues Glenmark Over Patent for Rosacea Drug FinaceaDawn McCarty
A unit of Bayer AG, Germany’s largest drugmaker, sued India’s Glenmark Generics Ltd. seeking to stop sales of a generic form of its Finacea gel used to treat rosacea.
Glenmark, based in Mumbai, is seeking U.S. Food and Drug Administration approval for a generic version of the drug before Bayer’s patent expires in 2018, according to a complaint filed yesterday in federal court in Wilmington, Delaware.
Plaintiffs will suffer “irreparable harm for which they have no adequate remedy at law” unless Glenmark is prohibited from using the technology before the patent expires, Bayer said in court papers.
“Based on available information, Glenmark believes it may be a first applicant” to file for the generic version of Finacea “and may be entitled to 180 days of generic market exclusivity,” Glenmark said in a statement today.
Finacea had U.S. sales of about $95 million for the 12 months ending Sept. 30, according to data compiled by IMS Health, a provider of health-care information, Glenmark said.
The case is Intendis GMBH v. Glenmark Generics Ltd., 13-cv-00421, U.S. District Court, District of Delaware (Wilmington).
To see the patent, click: 6,534,070.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Apple Is Secretly Developing Its Own Screens for the First Time
- Stocks Slump as Facebook Hits Tech; Bonds Recover: Markets Wrap
- Uber Halts Autonomous-Car Testing After Fatal Arizona Crash
- From a $126 Million Bonus to Jail: The Fall of a Star Trader
- Hong Kong's Richest Woman Loses Half Her Wealth on Stock Plunge